Related Experiment Videos
Embryonal rhabdomyosarcoma of the bladder and prostate in childhood
Insights
This study reports on 30 children with embryonal rhabdomyosarcoma, primarily in the bladder or prostate. Aggressive treatment combining surgery, radiotherapy, and chemotherapy is recommended for improved survival rates in pediatric rhabdomyosarcoma.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Medical Treatment
Background:
- Embryonal rhabdomyosarcoma is a rare pediatric cancer.
- The bladder and prostate are common primary sites for this tumor in children.
Purpose of the Study:
- To analyze treatment outcomes for pediatric embryonal rhabdomyosarcoma.
- To evaluate the effectiveness of combined treatment modalities.
Main Methods:
- Retrospective analysis of 30 children treated for embryonal rhabdomyosarcoma.
- Tumor sites (bladder/prostate), age at diagnosis, and survival rates were recorded.
- Treatment involved surgery, radiotherapy, and chemotherapy.
Main Results:
- The overall survival rate was 23% (7 out of 30 children survived).
- Patients with bladder rhabdomyosarcoma had a mean age of 3 years.
- Patients with prostate rhabdomyosarcoma had a mean age of 6.5 years.
- Survivors lived between 1.5 and 23 years postoperatively.
Conclusions:
- Aggressive, coordinated treatment is crucial for embryonal rhabdomyosarcoma.
- Combination therapy including surgery, radiotherapy, and chemotherapy offers the best chance for survival.
- Further research into optimizing treatment protocols for pediatric rhabdomyosarcoma is warranted.
Abstract:
Of 30 children treated for embryonal rhabdomyosarcoma the primary site of tumor was the bladder in 14 cases (9 boys and 5 girls) and the prostate in 16 cases. The mean age at diagnosis was 3 years in patients with bladder sarcoma and 6.5 years in patients with sarcoma of the prostate. Over-all survival rate has been 23 per cent--5 children with rhabdomyosarcoma of the bladder and 2 with rhadbomyosarcoma of the porstate are alive from 1 1/2 to 23 years postoperatively. Aggressive coordinated treatment with surgery, radiotherapy and cyclic combination chemotherapy is recommended.